Confidence in the potential for LumbaCurve in the provision of back pain relief is such that NWF (Biomedical)
The North West Fund for Biomedical is part of the wider £155m North West Fund, financed jointly by the European Regional Development Fund and the European Investment Bank.
The investment will be used by LumbaCurve for both market development and a clinical effectiveness study, which will be carried out by the University of Central Lancashire’s state of the art Movement Analysis Laboratory.
LumbaCurve is an ingenious but simple to use patented device, designed to provide relief to sufferers of lower back pain, by combining both East and West therapies techniques employed to combat back pain.
Positive trial results in its effectiveness as a back pain relief product will not only substantiate existing user testimonials, but will provide the medical credibility required to give LumbaCurve access to healthcare professionals, NHS sales, overseas distribution channels and retailers.
David Pegg, director of LumbaCurve, said: “We’re really pleased to have received this investment from SPARK, having struggled to raise finance from the usual channels. Although LumbaCurve has demonstrated time and time again that it works for back pain sufferers, we need to establish empirical evidence of its effectiveness in the treatment of back pain. We believe that this could open up potential opportunities to the worldwide healthcare market, which is looking for a back pain relief product that really works.”
Dr Penny Attridge, senior investment director at SPARK Impact and manager of The North West Fund for Biomedical, said: “Back pain is an endemic problem in western society with an estimated 40 per cent of adults experiencing the problem. LumbaCurve is an exciting product, which may have a genuine impact not only on how we treat lower back pain in the UK, but globally.”
The LumbaCurve back pain relief therapy can be seen at the Back Pain Show, Olympia, London 22/23 Feb
For further information go to www.lumbacurve.co.uk